Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions
Effects of other drugs on Lanifibranor
5 evidence topics · 3 sources
Metabolizing enzymes in vitro: CYP2C8, CYP2C19, CYP3A4, and UGT isoforms
Strong CYP2C8 inducers and inhibitors: exclusion and washout before treatment
Strong CYP2C8 inducers and inhibitors: prohibited concomitant medications, with rifampin, gemfibrozil, and clopidogrel as examples
Protocol amendment driven by preliminary results of drug-drug interaction study 337HVPK21014
Concomitant PPAR agonists: fibrates and thiazolidinediones excluded
Published results of drug-drug interaction study 337HVPK21014
No evidence found.